DK1117421T3 - Hidtil ukendte fremgangsmåder til terapuetisk vaccination - Google Patents

Hidtil ukendte fremgangsmåder til terapuetisk vaccination

Info

Publication number
DK1117421T3
DK1117421T3 DK99945967T DK99945967T DK1117421T3 DK 1117421 T3 DK1117421 T3 DK 1117421T3 DK 99945967 T DK99945967 T DK 99945967T DK 99945967 T DK99945967 T DK 99945967T DK 1117421 T3 DK1117421 T3 DK 1117421T3
Authority
DK
Denmark
Prior art keywords
new methods
therapeutic vaccination
vaccination
therapeutic
new
Prior art date
Application number
DK99945967T
Other languages
English (en)
Inventor
Dana Leach
Peter Birk Rasmussen
Lucilla Steinaa
Klaus Gregorius Nielsen
Jesper Haaning
Iben Dalum
Gunilla Karlsson
Soren Mouritsen
Anand Gautam
Original Assignee
Pharmexa As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmexa As filed Critical Pharmexa As
Priority claimed from EP99945967.0A external-priority patent/EP1117421B2/en
Application granted granted Critical
Publication of DK1117421T3 publication Critical patent/DK1117421T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001132—Fibroblast growth factors [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46443—Growth factors
    • A61K39/464432—Fibroblast growth factors [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464493—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A61K39/464495—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/58—Prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
DK99945967T 1998-10-05 1999-10-05 Hidtil ukendte fremgangsmåder til terapuetisk vaccination DK1117421T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199801261 1998-10-05
EP99945967.0A EP1117421B2 (en) 1998-10-05 1999-10-05 Methods for therapeutic vaccination

Publications (1)

Publication Number Publication Date
DK1117421T3 true DK1117421T3 (da) 2004-11-01

Family

ID=27675502

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99945967T DK1117421T3 (da) 1998-10-05 1999-10-05 Hidtil ukendte fremgangsmåder til terapuetisk vaccination

Country Status (5)

Country Link
EP (1) EP1502602A3 (da)
DK (1) DK1117421T3 (da)
ID (1) ID28387A (da)
SI (1) SI1117421T1 (da)
ZA (1) ZA200102603B (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008040759A1 (en) * 2006-10-03 2008-04-10 Pharmexa A/S Method for down-regulation of cripto
CN103091499B (zh) * 2013-01-23 2015-07-08 三峡大学 一种肿瘤标志物钙网蛋白检测试剂盒的制备及应用
CN116747298B (zh) * 2023-08-09 2024-01-02 成都新诺明生物科技有限公司 一种水痘-带状疱疹病毒疫苗及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
JP3926839B2 (ja) * 1993-09-14 2007-06-06 エピミューン，インコーポレイティド 万能ｄｒ−結合性ペプチドを用いる免疫応答の改変
AUPO390396A0 (en) * 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
GB9711957D0 (en) * 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
ES2255248T3 (es) * 1998-02-05 2006-06-16 Glaxosmithkline Biologicals S.A. Derivados de antigenos asociados a tumor de la familia mage, y secuencias de acidos nucleicos que los codifican, usados para la preparacion de proteinas de fusion y de composiciones para vacunas.

Also Published As

Publication number Publication date
SI1117421T1 (en) 2004-12-31
ZA200102603B (en) 2002-09-30
EP1502602A3 (en) 2006-05-17
EP1502602A2 (en) 2005-02-02
ID28387A (id) 2001-05-17

Similar Documents

Publication Publication Date Title
ID25792A (id) Antibodi-antibodi terhadap cd40 manusia
CY2013011I1 (el) Μεθοδος χορηγησης διφωσφονικων
DE60024988D1 (de) Herstellung von therapeutischem mikroschaum
ID27841A (id) Turunan-turunan biaril terapeutik
HUP0103976A3 (en) Novel methods for therapeutic vaccination
NO20040353L (no) Ny terapeutsk metode
NO20003067D0 (no) Antipicornavirus-forbindelser og fremgangsmÕter for deres anvendelse og fremstilling
NO20014950L (no) Nye behandlingsmetoder
PT1150966E (pt) Metodo de preparacao de 5-cianoftalido
ID27191A (id) Metode untuk pengobatan insomnia
NO986177L (no) FremgangsmÕte for fremstilling av terapeutisk DNA
IS5742A (is) Aðferð til genalækninga
EE04154B1 (et) Omeprasooli valmistamise meetod
EE200100623A (et) Melatoniini terapeutiline kasutamine
PT1178981E (pt) 3-piridil-4-arilpirrois substituidos e metodos terapeuticos e profilacticos
DK1117421T3 (da) Hidtil ukendte fremgangsmåder til terapuetisk vaccination
ID24922A (id) Terapi kombinasi untuk pengobatan aids
IT1283040B1 (it) Procedimento per la preparazione di acqua ossigenata
DE29818627U1 (de) Therapiestuhl
ID27014A (id) Metode yang lebih baik untuk pembuatan turunan-turunan norbenzomorfana yang bermanfaat secara farmasi
FI974235A0 (fi) Ny bestaemningsmetod
DK1047668T3 (da) Triazepinoner, fremgangsmåde til fremstilling deraf og terapeutisk anvendelse deraf
EE9900404A (et) Arüülaminotriasolopüridiinide valmistamise meetod
UA27992C2 (uk) Спосіб лікування онкологічних захворювань
ID24439A (id) Penggunaan tiazolidindion untuk pengobatan hiperglikemia